Skip to content

Effects of GV-971 and Donepezil in Alzheimer's Disease

Effects of GV-971 and Donepezil in Alzheimer's Disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047830
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-10
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer‘s Disease

Interventions

Group A:GV-971
Group B:Vehicle
Group C:GV-971+Donepezil
Group D:Vehicle+Donepezil

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 50 and 79 years old; 2. Both male and female; 3. Years of education >= 5 years; 4. The clinical dementia scale score is 0.5, and the memory module is at least 0.5; 5. MMSE score =12; 6. 18F-AV45-PET was positive or cerebrospinal fluid Abeta and tau detection showed AD-like changes; 7. No related drugs for AD symptoms have been used in the past 3 months; 8. Have reliable caregivers, meet the subjects at least five days a week, at least three hours a day, accompany the patients throughout the study, and be familiar with the subjects' health and personal care; 9. Patients and caregivers signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with cognitive impairment that may be caused by other reasons (vascular, infectious, metabolic, immune); 2) Those with fluctuating mental illness; 3. Those with abnormal cardiovascular and cardiac function; 4. Those with obvious respiratory system dysfunction; 5. Patients with abnormal renal function and liver function; 6. Those who clearly have coagulation disorders and tumor-related diseases; 7. Alcohol or drug abusers in the past 1 year; 8. Combination of drugs: other cognitive-improving drugs, such as other anticholinesterase inhibitors, memantine, Chinese patent medicines, etc., were taken during the treatment period.

Design outcomes

Primary

MeasureTime frame
Clinical Dementia Rating Scale Overall Score;

Secondary

MeasureTime frame
Simple Mental State Examination Scale;Alzheimer's Disease Rating Scale - Cognitive Subscale;Alzheimer's Disease Activities of Daily Living Inventory;

Countries

China

Contacts

Public ContactShen Yong

The First Affiliated Hospital of University of Science and Technology of China

meilishengling1990@163.com+86 15156073142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026